



Ocrevus Patient Referral Form

Patient Name: _____ Date: _____

SSN#: _____ DOB: _____ Primary Phone: _____ Work Phone: _____

Address: _____ City: _____ State: _____ Zip: _____

Primary Diagnosis: Please fill in appropriate ICD-10 code

G35 Multiple Sclerosis

Other ICD-10

1 Patient Information: In order to service your patient and facilitate insurance authorization, please complete the following.

Attach documents to FAX (see below)

NKDA Allergies: _____

Ht: _____ in/cm Wt: _____ lbs/kg Male Female

Is this the first Ocrevus infusion: Yes No

Date of last infusion: _____ Next dose due: _____

Line type: PIV PICC Port Other: _____ Lumen #: _____

- Copy of insurance card
Patient demographics
Labs
H&P
Immunization results, include HBV and TB

Other: _____

2 Clinical Information: ARJ policies and protocols to be provided upon request.

Table with 4 columns: Initial Dosing, Maintenance Dosing, Directions, Quantity/Refills. Includes Ocrevus dosing (300 mg/250 mL NS IV day 1 and day 15), maintenance (600 mg/500 mL NS IV every 6 months), and directions (infuse per manufacturer guidelines).

- RN to start peripheral IV or use existing CVC. RN to administer catheter flushing per ARJ Policy and Procedure
Give premedication 30 minutes prior to infusion (Note: If nothing is checked, no premeds will be given)
Diphenhydramine: 25-50 mg po OR 50 mg IV diluted in D5W or NS 50-100mL, infuse over 10-15 mins.
Antihistamine: Fexofenadine 180 mg po OR Cetirizine 10 mg po
Methylprednisolone: 100 mg slow IV push over 5 mins. OR mg slow IV push over 5 mins.
Acetaminophen: 325-650 mg po OR mg po

- RN to monitor vital signs at start of infusion, every 30 minutes and 1 hour post infusion. RN to educate patient on possible side effects, allergic reactions, and when to contact physician.
RN to instruct patient to hydrate pre/post infusion. RN to instruct patient to take Diphenhydramine 25-50 mg po and Acetaminophen 325-650 mg po every 4-6 hours for 24-48 hours as needed to prevent/treat post infusion headache.

Other: _____

- Adverse Reaction Orders: (Dispense 1 dose of each medication below)
For mild reactions such as: itching, flushing, rash - reduce the infusion rate to half the rate at the onset of reaction and maintain reduced rate for at least 30min.
For severe reactions such as: bronchospasm, dyspnea - stop infusion and administer appropriate medication based on symptoms occurring.
If infusion stopped infuse D5W or NS at 20 mL/hr to keep line open, may increase to 100-250 mL/hr for hydration.
Diphenhydramine: 50 mg IV diluted in D5W or NS 50-100 mL, infused over 10-15 minutes or 50 mg/10 mL NS IV push over 2-3 minutes, as tolerated.
Methylprednisolone: 125 mg (OR mg) slow IV push over 5 minutes.
Acetaminophen: 325-650 mg (OR mg) po at onset of symptoms.
Ondansetron: 4 mg slow IV push over 5 minutes or 4 mg ODT.
Epinephrine pen by weight for use IM or SQ in anaphylactic reaction. May repeat one time. EMS/911 will be called if used.
Albuterol inhaler: 90 mcg/inhalation, 1-2 puffs PRN bronchospasm.

3 Prescriber Information: By signing I certify that the use of the indicated treatment is medically necessary and I will be supervising the patient's treatment. ARJ Infusion Services has my permission to contact the patient's health plan to obtain any authorizations necessary to enable it to receive payment for services.

Physician Name: _____ Office Contact: _____

Address: _____ City: _____

State: _____ Zip: _____ Phone: _____ Fax: _____

License #: _____ DEA#: _____ NPI #: _____

Date: _____ | _____
Date: _____

Physician Signature Required - Substitution Permitted

Physician Signature Required - Dispense as Written

Confidential Health Information: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization and under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure and confidential manner. Re-disclosure of this information is prohibited by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state law. Important Warning: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any discrimination, distribution, or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately.